Anti-NGF ADCC Enhanced Antibody (PG110) is an ADCC enhanced antibody produced by our Afuco™ platform. PG110 is a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF). Phase I study to evaluate the safety, tolerability, and pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in patients with pain attributed to osteoarthritis of the knee.
Figure 1 Effects of PG110 on CFA-induced heat and mechanical hypersensitivity.
CFA treatment significantly decreased the mean ipsilateral PWL (A) and PWT (B) 5 days post treatment in 36 rats that were divided into four groups (vehicle group, n = 9; PG110 (10 µg/kg, n = 9); PG110 (30 µg/kg, n = 9) and PG110 (300 µg/kg, n = 9). The decrease in the mean ipsilateral PWL (A) and PWT (C), but not contralateral PWL (B) and PWT (D), was highly significant (P < 0.001) in all groups. Compared with vehicle (open columns), a single intravenous (via tail vein) administration of PG110 at 300 µg/kg (black columns) and 30 µg/kg (dark grey columns) caused a significant increase in the mean PWL at 48 h post post-drug treatment (A). This increase was highly significant for the doses of 300 µg/kg (P < 0.001) and 30 µg/kg (P < 0.01). However, the lowest dose (10 µg/kg) tested (light grey column) caused no significant change in the ipsilateral PWL. Note that PG110 at the doses tested (see above) had no effects on the mean contralateral PWL (B). Administration of PG110 at 300 µg/kg (black columns) also caused a significant increase in the mean ipsilateral (C), but not contralateral (D), PWT at 48 h post post-drug treatment.
Djouhri, L. (2016). PG110, a humanized anti-NGF antibody, reverses established pain hypersensitivity in persistent inflammatory pain, but not peripheral neuropathic pain, rat models. Pain Medicine, 17(11), 2082-2094.
Figure 2 Effects of PG110 on SNA-induced heat and mechanical hypersensitivity.
The mean ipsilateral PWL (A) and PWT (C) was significantly decreased 7 days after the nerve injury in 18 rats that were divided into two groups (vehicle group, n = 9; and PG110 (300 µg/kg, n = 9)). The decrease in the mean ipsilateral PWL and PWT was highly significant (P < 0.001) in both groups (A and C). However, SNA caused no apparent change in the mean contralateral PWL (B) or PWT (D). A single intravenous (via tail vein) administration of PG110 at 300 µg/kg (black columns) had no effect on the ipsilateral PWL (A) or PWT (C) at 48 h post post-drug treatment. Indeed the mean ipsilateral PWL and PWT after drug treatment (black column) were similar to those after vehicle (open column). Note that PG110 had no effects on the mean contralateral PWL (B) or PWT (D).
Djouhri, L. (2016). PG110, a humanized anti-NGF antibody, reverses established pain hypersensitivity in persistent inflammatory pain, but not peripheral neuropathic pain, rat models. Pain Medicine, 17(11), 2082-2094.
Figure 3 is a graph showing the binding of PG110 to human nerve growth factor (NGF) but not to human brain derived neurotrophic factor (BDNF), human neurotrophin 3 (NT-3) or human neurotrophin 4 (NT-4), as determined by ELISA.
Figure 4 is a graph showing inhibition of binding of NGF to the TrkA receptor by the PG 110 antibody, as determined by a radiolabeled ligand binding experiment.
Figure 5 is a graph showing inhibition of binding of NGF to the p75(NTR) receptor by the PG 110 antibody, as determined by a radiolabeled ligand binding experiment.
Figure 6 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by human NGF.
Figure 7 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by rat NGF.
Figure 8 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by mouse NGF.
Figure 9 is a graph showing the effect of PG 110 antibody treatment on skin lesioning in rats.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-111 | Anti-Human NGF Recombinant Antibody (Tanezumab) | ELISA, FuncS, Inhib | IgG2 |
TAB-686CL | Anti-Human NGF Therapeutical Antibody (PG110) | FuncS | Antibody |
TAB-501MZ | Anti-Human NGF Recombinant Antibody (αD11. H67) | ELISA | Humanized antibody |
TAB-501MZ-S(P) | Anti-Human NGF Recombinant Antibody scFv Fragment (αD11. H67) | ELISA, IRMA, RIA, IHC | Humanized antibody |
TAB-501MZ-F(E) | Anti-Human NGF Recombinant Antibody Fab Fragment (αD11. H67) | ELISA, IRMA, RIA, IHC | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-285 | Human Anti-NGF Recombinant Antibody (clone CNTO7309); Fab Fragment | WB, ELISA, IF, FuncS | Human Fab |
PFBL-286 | Human Anti-NGF Recombinant Antibody (clone mab 911); Fab Fragment | WB, ELISA, FuncS | Human Fab |
PFBL-659 | Human Anti-NGF Recombinant Antibody (clone APE1531); Fab Fragment | WB, FuncS | Human Fab |
HPAB-0275CQ-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (HPAB-0275CQ-F(E)) | ELISA, Neut | Human Fab |
HPAB-0385-WJ-F(E) | Mouse Anti-NGF Recombinant Antibody; Fab Fragment (HPAB-0385-WJ-F(E)) | ELISA, FC | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0331CL | Mouse Anti-NGF Recombinant Antibody (TAB-0331CL) | Neut, ELISA, Inhib, FuncS | Mouse IgG |
TAB-500MZ-F(E) | Anti-Human NGF Recombinant Antibody Fab Fragment (MNAC13) | ELISA, IRMA, RIA, IHC | |
PABX-146-F (E) | Recombinant Rat Anti-NGF Antibody Fab Fragment (αD11) | Neut, FC, FuncS | Fab |
TAB-025ML | Anti-Feline NGF Recombinant Antibody (Frunevetmab) | ELISA, IHC, FC, IP, IF, Inhib | IgG1, κ |
TAB-031ML | Anti-Canine NGF Recombinant Antibody (Ranevetmab) | ELISA, IHC, FC, IP, IF, Inhib | IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-509MZ | Human Anti-NGF Recombinant Antibody (TAB-509MZ) | ELISA | Chimeric (mouse/human) IgG |
TAB-510MZ | Human Anti-NGF Recombinant Antibody (TAB-510MZ) | ELISA, FuncS | Chimeric (mouse/human) IgG |
TAB-509MZ-S(P) | Mouse Anti-NGF Recombinant Antibody; scFv Fragment (TAB-509MZ-S(P)) | ELISA | Mouse scFv |
TAB-510MZ-S(P) | Mouse Anti-NGF Recombinant Antibody; scFv Fragment (TAB-510MZ-S(P)) | ELISA | Mouse scFv |
TAB-509MZ-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (TAB-509MZ-F(E)) | ELISA | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-512MZ-S(P) | Human Anti-NGF Recombinant Antibody; scFv Fragment (TAB-512MZ-S(P)) | ELISA, RIA, FC | Human scFv |
TAB-513MZ-S(P) | Human Anti-NGF Recombinant Antibody; scFv Fragment (TAB-513MZ-S(P)) | ELISA, RIA, FC | Human scFv |
TAB-488MZ-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (TAB-488MZ-F(E)) | ELISA | Human Fab |
TAB-489MZ-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (TAB-489MZ-F(E)) | ELISA | Human Fab |
TAB-490MZ-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (TAB-490MZ-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0852MZ | Chicken Anti-NGF Polyclonal IgY | ELISA | Chicken antibody |
BRD-1134MZ | Chicken Anti-Beta NGF Polyclonal IgY | ELISA, WB, IHC | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PABX-146-S (P) | Rat Anti-NGF Recombinant Antibody (clone αD11) | Neut, FC, FuncS | Rat scFv |
MOR-2439 | Hi-Affi™ Recombinant Rabbit Anti-NGF Monoclonal Antibody (DS2439AB) | WB, ICC, IHC-P, IHC-P | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1764CQ | Recombinant Mouse Anti-NGF Antibody (CBL293) | Neut | IgG1 |
NEUT-1765CQ | Recombinant Mouse Anti-NGF Antibody (12A29) | ELISA, Neut | IgG1 |
NEUT-1766CQ | Recombinant Mouse Anti-NGF Antibody (M85-2B) | ELISA, Neut, WB | IgG2b, κ |
NEUT-1767CQ | Recombinant Mouse Anti-Ngf Antibody (27/21) | ELISA, Neut | IgG1 |
NEUT-1769CQ | Recombinant Mouse Anti-NGF Antibody (AS18) | Neut | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1768CQ | Recombinant Mouse Anti-NGF Antibody (aD11) | IF, BL, ELISA, IHC | IgG1, κ |
NEUT-1772CQ | Recombinant Mouse Anti-NGF Antibody (25623.1) | Dot, ELISA, Inhib | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0688-CN-S(P) | Human Anti-NGF Recombinant Antibody; scFv Fragment (HPAB-0688-CN-S(P)) | WB, ELISA | Human scFv |
HPAB-0275CQ-S(P) | Human Anti-NGF Recombinant Antibody; scFv Fragment (HPAB-0275CQ-S(P)) | ELISA, Neut | Human scFv |
HPAB-0900-FY-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (HPAB-0900-FY-F(E)) | WB, FC | Humanized Fab |
HPAB-1789-FY-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (HPAB-1789-FY-F(E)) | ELISA | Humanized Fab |
HPAB-1790-FY-F(E) | Human Anti-NGF Recombinant Antibody; Fab Fragment (HPAB-1790-FY-F(E)) | ELISA, IHC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0275CQ | Human Anti-NGF Recombinant Antibody (HPAB-0275CQ) | ELISA, Neut, FuncS | Human IgG2 |
HPAB-0385-WJ | Mouse Anti-NGF Recombinant Antibody (HPAB-0385-WJ) | ELISA, FC, FuncS | Mouse IgG |
HPAB-1789-FY | Human Anti-NGF Recombinant Antibody (HPAB-1789-FY) | Block, Inhib, SPR, Antagonist | Human IgG |
HPAB-1790-FY | Human Anti-NGF Recombinant Antibody (HPAB-1790-FY) | ELISA, IHC | Human IgG |
HPAB-1791-FY | Human Anti-NGF Recombinant Antibody (HPAB-1791-FY) | ELISA, IHC | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-025ML | Afuco™ Anti-NGF ADCC Recombinant Antibody (Frunevetmab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
AFC-TAB-031ML | Afuco™ Anti-NGF ADCC Recombinant Antibody (Ranevetmab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
AFC-TAB-111 | Afuco™ Anti-NGF ADCC Recombinant Antibody (Tanezumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-110 | Afuco™ Anti-NGF Recombinant Antibody (AFC-TAB-110), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | Human IgG1, κ |
There are currently no Customer reviews or questions for AFC-659CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.